A Canadian open-label study to evaluate the safety and effectiveness of adalimumab when added to inadequate therapy for the treatment of psoriatic arthritis (PsA) (ACCLAIM)

Trial Profile

A Canadian open-label study to evaluate the safety and effectiveness of adalimumab when added to inadequate therapy for the treatment of psoriatic arthritis (PsA) (ACCLAIM)

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms ACCLAIM
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 17 Jun 2017 Results of post-hoc analysis data from two studies (ACCLAIM and ADEPT) presented at the 18th Annual Congress of the European League Against Rheumatism
    • 03 May 2008 Status changed from in progress to completed
    • 20 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top